Founded Year

2011

Stage

Series D | Alive

Total Raised

$127.52M

Last Raised

$71M | 2 yrs ago

About Sight Diagnostics

Sight Diagnostics provides affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. Its proprietary machine-vision based technology provides the capability to perform multiple tests on a single, easy-to-operate platform.

Sight Diagnostics Headquarter Location

23 Menahem Begin Street

Tel Aviv, 6618356,

Israel

ESPs containing Sight Diagnostics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Medical Devices Tech

Point-of-care (POC) testing refers to diagnostic lab tests that can be performed rapidly, reliably, and easily at or near the point of care. Starting with a biological sample, POC tests detect or quantify certain analytes — such as infectious agents, cardiac markers, and blood glucose — to inform clinical decision making.

Sight Diagnostics named as Outperformer among 15 other companies, including BD, Accellix, and Genalyte.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Sight Diagnostics's Products & Differentiation

See Sight Diagnostics's products and how their products differentiate from alternatives and competitors

  • Sight OLO

    AI-based blood diagnostics analyzer that offers lab-grade Complete Blood Count (CBC) results from two drops of blood in minutes. OLO leverages a patented method of “digitizing” blood samples and is built with high-powered microscopes, computer vision, and artificial intelligence, allowing it to deliver lab-quality results in a much more compact and efficient format than traditional CBC machines. The analyzer’s computer vision technology produces over 1,000 highly detailed images of blood from each blood sample and then deploys fully automated AI algorithms to measure, classify, and count the different cells and identify abnormalities, measuring 19 different parameters with 5-part differentials, including full flagging capabilities.

    Differentiation

    Current CBC analyzers require a trained healthcare professional to draw a significant amount of blood from a patient, which then needs to be transferred to a central lab. From there, it can take hou… 

Research containing Sight Diagnostics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sight Diagnostics in 2 CB Insights research briefs, most recently on Feb 16, 2022.

Expert Collections containing Sight Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sight Diagnostics is included in 6 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

11,970 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

3,408 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

D

Digital Hospital

100 items

H

Health IT

8,260 items

Latest Sight Diagnostics News

03:21 ET Sight Diagnostics® and Inter Medico Announce the Health Canada Approval of Sight OLO for Point-of-Care Testing

Jan 11, 2022

News provided by Share this article Share this article Approval marks Health Canada's first 5-part differential for Complete Blood Count testing that only requires 2 drops of blood TEL AVIV, Israel, Jan. 11, 2022 /CNW/ --  Sight Diagnostics , the company delivering lab-grade Complete Blood Count (CBC) results in minutes, today announced it has received Health Canada approval to provide Sight OLO® analyzers for point-of-care settings. Through its distribution partner Inter Medico, Sight will bring the first and only 5-part differential CBC testing to emergency departments, hospitals, and other decentralized settings across Canada. Sight OLO Due to the sparsely populated nature of Canada, many small hospitals are spread out throughout the provinces, making decentralized testing critical. With Sight OLO, users draw blood from a finger prick sample and in minutes, receive 5-part differential results that can be used for clinical diagnosis. The analyzer has no maintenance and has a simple cartridge-based setup. Grey Bruce Health Services in Owen Sound, Ontario was a trial site for Sight OLO and Tom Blashill, Charge Technologist Hematology, commented: "Small, sleek with a super intuitive display Sight OLO is something you'd expect to see in an Apple store. This is not hyperbole; this device delivers accurate and precise results as advertised with minimal effort." Blashill went on to comment on the ease of use. "For smaller centers like a doctor's office or smaller hospital, this is the perfect fit. The reagents are all embedded in the test kit, so there is no need to store and manage liquid reagents or waste. In short, I would not hesitate to recommend this device as a replacement for traditional CBC analyzers for low volume situations." "The Health Canada approval for point-of-care testing opens up a wide range of avenues for Sight OLO to be used to support clinicians in making fast, accurate, actionable treatment decisions," said Yossi Pollak, CEO and Cofounder of Sight Diagnostics. "Now anyone, not just hospitals, but nurses, lab technicians, smaller practice physicians, and more, have access to 5-part differential CBC testing." In April 2021, Sight announced Health Canada approval to provide Sight OLO analyzers to laboratories and this new point-of-care approval expands Sight's market reach even broader throughout Canada to small rural and remote laboratories, hospitals, and health centers. For example, through Sight's partner AA Pharma, psychiatry clinics can leverage Sight OLO to monitor patients' blood who are receiving Clozapine treatment. For other partners interested in leveraging Sight OLO in remote settings, contact: [email protected] *This press release is intended for audiences in Canada. In Canada, Sight OLO received a Medical Device License from Health Canada for use in laboratories and point-of-care use. Outside of Canada, Sight OLO is CE Marked and listed in the Australian Register of Therapeutic Goods with a point of care indication. For full indications for use and safety information please refer to the Quality and Compliance page at www.sightdx.com . About Sight Diagnostics Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and convenient diagnostic testing. Sight's technology, developed over a decade of research, represents breakthrough innovations in artificial intelligence (AI) sample processing. Sight's latest blood analyzer, OLO, performs a Complete Blood Count, the most commonly ordered blood test worldwide, in just minutes. OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a fingerprick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight's first product, ParasightTM, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the US, UK, and Israel. Learn more at www.SightDX.com . About Inter Medico Inter Medico specializes in providing leading edge instrumentation and reagent solutions to Canadian customers. We are proud of the success we have achieved over the past 40 years based on our dedicated service and support. Our organization consists of a matrix of front-line support through our bilingual customer support team, a coast-to-coast network of Account Managers and Field Service Engineers. Our technical support team is ready to answer any questions related to our reagents and instrumentation through our bilingual 24-hour, 7 day a week 1-800 hotline. Learn more at www.Inter-Medico.com . Gabriela Lund

Sight Diagnostics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sight Diagnostics Rank

  • When was Sight Diagnostics founded?

    Sight Diagnostics was founded in 2011.

  • Where is Sight Diagnostics's headquarters?

    Sight Diagnostics's headquarters is located at 23 Menahem Begin Street, Tel Aviv.

  • What is Sight Diagnostics's latest funding round?

    Sight Diagnostics's latest funding round is Series D.

  • How much did Sight Diagnostics raise?

    Sight Diagnostics raised a total of $127.52M.

  • Who are the investors of Sight Diagnostics?

    Investors of Sight Diagnostics include OurCrowd, Longliv Ventures, Koch Disruptive Technologies, New Alliance Capital, Steven Esrick and 8 more.

  • Who are Sight Diagnostics's competitors?

    Competitors of Sight Diagnostics include Visby Medical, OncoHost, Cardea Bio, Baebies, Oxford Immune Algorithmics, Noul, PixCell Medical Technologies, MeMed, Accellix, Inflammatix and 29 more.

  • What products does Sight Diagnostics offer?

    Sight Diagnostics's products include Sight OLO.

You May Also Like

Truvian Sciences Logo
Truvian Sciences

Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.

BD Logo
BD

BD is a medical technology company that manufactures and sells a broad range of supplies, devices, and systems for use by healthcare professionals, medical research institutions, industry, and the general public.

Cepheid Logo
Cepheid

Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid previously traded under the ticker NASDAQ: CPHD.

MeMed Logo
MeMed

MeMed is a med-tech and bio-convergence firm that researches, develops, and commercializes diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes.

D
DiaSorin

DiaSorin is a multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. It is based in Saluggia, Italy.

Baebies Logo
Baebies

Baebies developed a nimble bioassay automation platform to rapidly perform multiplex enzymatic assays and other tests. The company licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. The company was founded in 2013 and is based in Durham, North Carolina.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.